774605-58-2

Usage

Uses

Used in Pharmaceutical Industry:
3-(2,6-Dichlorophenyl)-5-isopropylisoxazole-4-carboxylic acid is used as an active pharmaceutical ingredient for the development of prescription and over-the-counter medications. It is particularly effective in the treatment of arthritis, menstrual pain, and other inflammatory conditions due to its ability to inhibit the synthesis of prostaglandins, which are the primary mediators of inflammation and pain.
Used in Pain Management:
In the field of pain management, 3-(2,6-Dichlorophenyl)-5-isopropylisoxazole-4-carboxylic acid serves as a potent analgesic agent. Its mechanism of action involves the inhibition of prostaglandin synthesis, thereby reducing pain sensations and providing relief to patients suffering from various types of pain.
Used in Anti-inflammatory Treatments:
3-(2,6-Dichlorophenyl)-5-isopropylisoxazole-4-carboxylic acid is utilized as an anti-inflammatory agent in various treatments. Its effectiveness in reducing inflammation is attributed to its ability to block the production of prostaglandins, which are responsible for the inflammatory response in the body.
Used in Antipyretic Formulations:
As an antipyretic, 3-(2,6-Dichlorophenyl)-5-isopropylisoxazole-4-carboxylic acid is incorporated into formulations designed to reduce fever. Its action in lowering body temperature is beneficial in managing conditions associated with elevated temperatures, such as infections or heatstroke.

Upstream product

• 278597-28-7 methyl 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carboxylate 
• 83-38-5 2,6-dichlorobenzaldehyde 
• 6579-27-7 2,6-dichlorobenzohydroximoyl chloride 
• 25185-95-9 2,6-dichlorobenzaldoxime 
• 6579-27-7 2,6-Dichloro-N-hydroxybenzenecarboximidoyl chloride 
• 6575-28-6 (1E)-2,6-dichlorobenzaldehyde oxime 
• 7152-15-0 ethyl 4-methyl-3-oxo-pentanoate 
• 774605-35-5 ethyl 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carboxylate 

Relevant academic research and scientific papers

Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast

The nuclear farnesoid X receptor (FXR) and the enzyme soluble epoxide hydrolase (sEH) are validated molecular targets to treat metabolic disorders such as non-alcoholic steatohepatitis (NASH). Their simultaneous modulation in vivo has demonstrated a triad of anti-NASH effects and thus may generate synergistic efficacy. Here we report dual FXR activators/sEH inhibitors derived from the anti-asthma drug Zafirlukast. Systematic structural optimization of the scaffold has produced favorable dual potency on FXR and sEH while depleting the original cysteinyl leukotriene receptor antagonism of the lead drug. The resulting polypharmacological activity profile holds promise in the treatment of liver-related metabolic diseases.

ISOXAZOLE DERIVATIVE AS MUTATED ISOCITRATE DEHYDROGENASE 1 INHIBITOR

It has been found that a compound of the general formula (I) having an isoxazole skeleton has excellent inhibitory activity against mutant IDH1 protein and inhibits the production of 2-HG by this protein, while the compound is also capable of effectively inhibiting the growth of various tumors expressing the protein. In the formula, R1, R2, R3, Y, and Z are as defined in claim 1.

Isoxazole carboxamide derivatives as ghrelin receptor modulators

The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.

Novel isoxazole carboxamides as growth hormone secretagogue receptor (GHS-R) antagonists

Novel isoxazole carboxamides have been identified as growth hormone secretagogue receptor (GHS-R) antagonists. Substituent modification off the 5-position of the isoxazole ring led to analogues with potent binding affinity and functional antagonism of GHS-R. A potent analogue (32) with high aqueous solubility and good GPCR selectivity was also identified as a potential pharmacological tool for in vivo studies.